Hansruedi Loetscher

Roche, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport.

Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport.

Journal: EBioMedicine

Published: March 24, 2017

Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.

Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.

Journal: The Journal of pharmacology and experimental therapeutics

Published: March 24, 2017

Region-specific permeability of the blood-brain barrier upon pericyte loss.

Region-specific permeability of the blood-brain barrier upon pericyte loss.

Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

Published: March 10, 2017

Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier.

Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier.

Journal: Scientific reports

Published: October 09, 2015

Cargo Delivery into the Brain by in vivo identified Transport Peptides.

Cargo Delivery into the Brain by in vivo identified Transport Peptides.

Journal: Scientific reports

Published: April 08, 2015

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.

Journal: Neuron

Published: October 08, 2013

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Journal: Archives of neurology

Published: October 12, 2011

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.

Journal: Journal of Alzheimer's disease : JAD

Published: September 30, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026